Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
G-NaK is an oral electrolyte replacement therapy formulated as a combination of potassium gluconate, potassium citrate, and sodium citrate. It is primarily indicated for the management of electrolyte imbalances, specifically potassium and sodium depletion, and for the prevention of metabolic acidosis. The potassium and sodium ions provided are essential for maintaining osmotic pressure, nerve impulse transmission, and muscle contraction. The citrate and gluconate components are metabolized in the body to bicarbonate, which serves as a systemic alkalinizing agent to help restore or maintain systemic acid-base balance. It is commonly used in clinical settings where patients experience chronic electrolyte loss or require supplementation due to renal or metabolic conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on G-NaK.